In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 6, 2011, Pages

  Lee, Jung Pyo ^a,b   Yang, Seung Hee ^a   Kim, Dong Ki ^b   Lee, Hajeong ^b   Kim, Bora ^b   Cho, Joo Youn ^b   Yu, Kyung Sang ^b   Paik, Jin Ho ^b   Kim, Myounghee ^a   Lim, Chun Soo ^a,b   Kim, Yon Su ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Single nucleotide polymorphisms; Soluble epoxide hydrolase

Indexed keywords

EPOXIDE HYDROLASE;

ADULT; ALLELE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IN VIVO STUDY; KIDNEY BIOPSY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 79958110175     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00733.2010     Document Type: Article

References (33)

1. Anonymous. The Internationl HapMap Consortium. The International HapMap Project. Nature 426: 789-796, 2003.
2. Bantis C, Ivens K, Kreusser W, Koch M, Klein-Vehne N, Grabensee B, Heering P. Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol 24: 258-267, 2004.
3. Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res 5: 128-134, 2008.
4. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
5. D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G, Imbasciati E, Ragni A, Bertoli S, Fogazzi G, Duca G. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 59: 363-378, 1986.
6. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 347: 738-748, 2002.
7. Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, Rice JB, Hammock BD, Spector AA. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 287: H2412-H2420, 2004.
8. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
9. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109: 335-339, 2004.
10. Heizer ML, McKinney JS, Ellis EF. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 22: 1389-1393, 1991.
11. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-F503, 2005.
12. Kim SM, Chin HJ, Oh YK, Kim YS, Kim S, Lim CS. Blood pressurerelated genes and the progression of IgA nephropathy. Nephron Clin Pract 113: c301-c308, 2009.
13. Kim SY, Jin DC, Bang BK. Current status of dialytic therapy in Korea. Nephrology (Carlton) 8, Suppl: S2-S9, 2003.
14. Kim YS, Kang D, Kwon DY, Park WY, Kim H, Lee DS, Lim CS, Han JS, Kim S, Lee JS. Uteroglobin gene polymorphisms affect the progression of immunoglobulin A nephropathy by modulating the level of uteroglobin expression. Pharmacogenetics 11: 299-305, 2001.
15. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15: 1640-1649, 2006.
16. Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 57: 116-122, 2010.
17. Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, Park SY, Han JS, Kim S, Lee JS. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 20: 342-348, 2005.
18. Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S, Kim YS. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 40: 1353-1356, 2008.
19. Lim CS, Kim SM, Oh YK, Kim YS, Chae DW, Han JS, Kim S, Lee JS, Yoon HJ. Association between the clara cell secretory protein (CC16) G38A polymorphism and the progression of IgA nephropathy. Clin Nephrol 67: 73-80, 2007.
20. Newman JW, Watanabe T, Hammock BD. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 43: 1563-1578, 2002.
21. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999.
22. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64: 482-490, 2003.
23. Saito S, Iida A, Sekine A, Eguchi C, Miura Y, Nakamura Y. Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (EPHX1 and EPHX2) in the Japanese population. J Hum Genet 46: 325-329, 2001.
24. Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 275: 28873-28881, 2000.
25. Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, Umemura S, Xin Y, Wu LL, Larrinaga-Shum S, Stephenson SH, Hunt SC, Hopkins PN. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 49: 29-34, 2004.
26. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 89: 209-215, 1990.
27. Schmid H, Cohen CD, Henger A, Irrgang S, Schlondorff D, Kretzler M. Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. Kidney Int 64: 356-360, 2003.
28. Shinzato T, Nakai S, Akiba T, Yamagami S, Yamazaki C, Kitaoka T, Kubo K, Maeda K, Morii H. Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 55: 700-712, 1999.
29. Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 427: 164-169, 2004.
30. Syrjanen J, Huang XH, Mustonen J, Koivula T, Lehtimaki T, Pasternack A. Angiotensin-converting enzyme insertion/deletion polymorphism and prognosis of IgA nephropathy. Nephron 86: 115-121, 2000.
31. Yoshimura K, Hanaoka T, Ohnami S, Kohno T, Liu Y, Yoshida T, Sakamoto H, Tsugane S. Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet 48: 654-658, 2003.
32. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 286: F720-F726, 2004.
33. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062, 2001.